Form 4 for BDX Becton Dickinson
Accepted 2026-08-14 16:36:21 ET · period of report 2026-08-13 · accession 0001628280-26-057166 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-08-14 16:36 | 2026-08-13 | BDX | Polen Thomas E Jr | COB, CEO, Pres, Dir | M - OptEx | $167.25 | +43.3K | 153.4K | +39% | +$7.24M |
| DT | 2026-08-14 16:36 | 2026-08-13 | BDX | Polen Thomas E Jr | COB, CEO, Pres, Dir | D - Sale to Iss | $185.00 | -39.1K | 114.3K | -25% | -$7.24M |
| DT | 2026-08-14 16:36 | 2026-08-13 | BDX | Polen Thomas E Jr | COB, CEO, Pres, Dir | S - Sale+OE | $185.00 | -4,152 | 110.2K | -4% | -$768.1K |
| DT | 2026-08-14 16:36 | 2026-08-13 | BDX | Polen Thomas E Jr | COB, CEO, Pres, Dir | M - OptEx | $0.00 | -43.3K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-13 | M | A | 43,278 | $167.25 | 153,441 | D | — | — | |
| 2 | Common | Common Stock | 2026-08-13 | D | D | 39,126 | $185.00 | 114,315 | D | — | — | |
| 3 | Common | Common Stock | 2026-08-13 | S | D | 4,152 | $185.00 | 110,163 | D | — | — | |
| 4 | Derivative | Stock Appreciation Rights | 2026-08-13 | M | D | 43,278 | $0.00 | 0 | D | $167.25 · 2018-11-26 to 2027-11-26 | 43,278 Common Stock | (F1) Award terms reflect the adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. (F2) The stock appreciation rights vested in four annual installments beginning November 26, 2018. |